Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities

Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis free survival in M0 CRPC patients and have been approved by regulatory agencies in Brazil...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International Brazilian Journal of Urology 2021-03, Vol.47 (2), p.359-373
Hauptverfasser:	Maluf, Fernando, Soares, Andrey, Avanço, Guilherme, Hada, Aline Lury, Cardoso, Ana Paula Garcia, Carneiro, Arie, Herchenhorn, Daniel, Jardim, Denis Leonardo Fontes, Schutz, Fabio Augusto, Kater, Fabio Roberto, Pereira, Felipe Moraes Toledo, Monteiro, Fernando Sabino Marques, Morbeck, Igor Alexandre Protzner, Reolon, João Francisco Navarro, da Trindade, Karine Martins, Andrade, Livia Maria Querino da Silvo, Nogueira, Lucas Mendes, Furoni, Renato, Natel, Ricardo Azze, Dos Reis, Rodolfo Borges, Fogace, Rodrigo Nogueira, Souza, Vinicius Carrera
Format:	Artikel
Sprache:	eng
Schlagworte:	Brazil Consensus Humans Male Original Patient Selection Perception Physicians Prostate cancer, familial [Supplementary Concept] Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms, Castration-Resistant - diagnosis Prostatic Neoplasms, Castration-Resistant - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!